Year Book of RCC 2020

出版社： メディカルレビュー社
著者：
発行日： 2021-02-03
分野： 臨床医学：内科  >  腎臓
ISBN： 9784779223716
電子書籍版： 2020-12-22 （第1版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

5,280 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

5,280 円(税込)

購入する

商品紹介

IO＋TKI併用療法施行症例に焦点を当てたディスカッションを行うほか、1次治療におけるIO併用療法の治療選択や、リスク分類別の観点からの腎細胞癌の長期成績等を解説。「腎癌取扱い規約第5版」改訂のポイントも収録。

目次

  • I　Round Table Discussion
    　　IO+TKI併用療法の実際

    II　Topics of RCC　1次治療におけるIO併用療法の治療選択：IO+IO or IO+TKI
    　１．各併用療法の長所と短所
    　２．IO併用療法時代における進行腎細胞癌に対する至適薬物療法戦略
    　３．アプローチ別のレジメン選択

    III　RCC Long-term prognosis
    　　RCC 薬物療法のリスト分類別の長期成績改善の変遷
    　１．Favorable risk
    　２．Intermediate risk
    　３．Poor risk

    IV　特別寄稿
    　『腎癌取扱い規約第5版』改訂のポイント

    V　付録
    　　RCC関連演題の一覧（ASCO 2020，ESMO 2020）

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

I Round Table Discussion

P.17 掲載の参考文献
1) Amin A, et al. Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma : the CheckMate 016 study. J Immunother Cancer. 2018 ; 6 : 109.
 
2) Escudier B, et al. Efficacy of Nivolumab plus Ipilimumab According to Number of IMDC Risk Factors in CheckMate 214. Eur Urol. 2020 ; 77 : 449-53.
PubMed
3) Tannir NM, et al. Overall survival and independent review of response in CheckMate 214 with 42-month follow-up : First-line nivolumab + ipilimumab (N+I) versus sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC). J Clin Oncol. 2020 ; 38 Suppl : 609.
 
4) Powles T, et al. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426) : extended follow-up from a randomised, open-label, Phase 3 trial. Lancet Oncol. 2020. Online ahead of print.
 
5) Tomita Y, et al. Treatment-free survival after discontinuation of immuno-checkpoint therapy, and outcome of subsequent molecular targeted therapy : Retrospective study of Japanese metastatic renal cell carcinoma patients (after I-O study). J Clin Oncol. 2020 ; 38 Suppl : 677.
 

II Topics of RCC 1次治療におけるIO併用療法の治療選択 : IO + IO or IO + TKI

P.24 掲載の参考文献
1) 日本泌尿器科学会 (編). 腎癌診療ガイドライン 2017年版 2020年アップデート. 2020. https://www.urol.or.jp/lib/files/other/guideline/33_renal_cancer_2017_rev2020_info.pdf, (閲覧 : 2020-10-02)
 
2) Motzer RJ, et al. Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma : 42-month follow-up of a randomized phase 3 clinical trial. J Immunother Cancer. 2020 ; 8 : e000891.
PubMed
3) Cella D, et al. Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214) : a randomised, phase 3 trial. Lancet Oncol. 2019 ; 20 : 297-310.
PubMed
4) Dudani S, et al. First-line Immuno-Oncology Combination Therapies in Metastatic Renal-cell Carcinoma : Results from the International Metastatic Renal-cell Carcinoma Database Consortium. Eur Urol. 2019 ; 76 : 861-7.
PubMed
5) Shi LZ, et al. Interdependent IL-7 and IFN-g signalling in T-cell controls tumour eradication by combined α-CTLA-4+α-PD-1 therapy. Nat Commun. 2016 ; 7 : 12335.
 
6) Motzer RJ, et al. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. N Engl J Med. 2018 ; 378 : 1277-90.
PubMed
7) Rini BI, et al. Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med. 2019 ; 380 : 1116-27.
PubMed
8) Powles T, et al. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426) : extended follow-up from a randomised, openlabel, Phase 3 trial. Lancet Oncol. 2020. Online ahead of print.
 
9) Cao G, et al. What is the optimum systemic treatment for advanced/metastatic renal cell carcinoma of favourable, intermediate and poor risk, respectively? A systematic review and network meta-analysis. BMJ Open. 2020 ; 10 : e034626.
PubMed
10) Monteiro FSM, et al. First-line Treatment of Metastatic Renal Cell Carcinoma in the Immunooncology Era : Systematic Review and Network Meta-analysis. Clinical GenitoUrinary Cancer. 2020 ; 18 : 244-51.
 
11) McDermott DF, et al. Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nat Med. 2018 ; 24 : 749-57.
 
12) Tanegashima T, et al. Immune Suppression by PD-L2 against Spontaneous and Treatment-Related Antitumor Immunity. Clin Cancer Res. 2019 ; 25 : 4808-19.
PubMed
13) Motzer RJ, et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019 ; 380 : 1103-15.
PubMed
14) Choueiri TK, et al. Updated efficacy results from the JAVELIN Renal 101 trial : first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma. Ann Oncol. 2020 ; 31 : 1030-9.
PubMed
P.33 掲載の参考文献
1) Parton M, et al. Role of cytokine therapy in 2006 and beyond for metastatic renal cell cancer. J Clin Oncol. 2006 ; 24 : 5584-92.
PubMed
2) Calvo E, et al. Improvement in survival end points of patients with metastatic renal cell carcinoma through sequential targeted therapy. Cancer Treat Rev. 2016 ; 50 : 109-17.
PubMed
3) Motzer RJ, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015 ; 373 : 1803-13.
PubMed
4) Motzer RJ, et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med. 2018 ; 378 : 1277-90.
PubMed
5) Rini BI, et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019 ; 380 : 1116-27.
PubMed
6) Motzer RJ, et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019 ; 380 : 1103-15.
PubMed
7) Motzer RJ, et al. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma : extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. Lancet Oncol. 2019 ; 20 : 1370-85.
PubMed
8) Powles T, et al. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426) : extended follow-up from a randomised, openlabel, Phase 3 trial. Lancet Oncol. 2020. Online ahead of print.
 
9) Choueiri TK, et al. Updated efficacy results from the JAVELIN Renal 101 trial : first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma. Ann Oncol. 2020 ; 31 : 1030-9.
PubMed
10) Escudier B. Combination Therapy as First-Line Treatment in Metastatic Renal-Cell Carcinoma. N Engl J Med. 2019 ; 380 : 1176-8.
PubMed
11) Michot JM, et al. Immune-related adverse events with immune checkpoint blockade : a comprehensive review. Eur J Cancer. 2016 ; 54 : 139-48.
PubMed
12) Mori K, et al. Systemic therapy for metastatic renal cell carcinoma in the first-line setting : a systematic review and network meta-analysis. Cancer Immunol Immunother. 2020. Online ahead of print.
 
13) Cao G, et al. What is the optimum systemic treatment for advanced/metastatic renal cell carcinoma of favourable, intermediate and poor risk, respectively? A systematic review and network meta-analysis. BMJ Open. 2020 ; 10 : e034626.
PubMed
14) Alam MU, et al. Combination Therapy for Metastatic Renal Cell Carcinoma : A Systematic Review and Network Meta-analysis. Am J Clin Oncol. 2020 ; 43 : 477-83.
PubMed
15) Hahn AW, et al. First-line Treatment of Metastatic Renal Cell Carcinoma : A Systematic Review and Network Meta-analysis. Eur Urol Oncol. 2019 ; 2 : 708-15.
PubMed
16) Aggen DH, et al. Targeting PD-1 or PD-L1 in metastatic kidney cancer : combination therapy in the first-line setting. Clin Cancer Res. 2020 ; 26 : 2087-95.
 
17) Menon S, et al. Advances in cancer immunotherapy in solid tumors. Cancers. 2016 ; 8 : 106.
 
18) Nadal R, et al. Safety and clinical activity of vascular endothelial growth factor receptor (VEGFR) -tyrosine kinase inhibitors after programmed cell death 1 inhibitor treatment in patients with metastatic clear cell renal cell carcinoma. Ann Oncol. 2016 ; 27 : 1304-11.
PubMed
19) Barata PC, et al. The efficacy of VEGFR TKI therapy after progression on immune combination therapy in metastatic renal cell carcinoma. Br J Cancer. 2018 ; 119 : 160-3.
PubMed
20) Dudani S, et al. First-line immuno-oncology combination therapies in metastatic renal-cell carcinoma : results from the International Metastatic Renal-cell Carcinoma Database Consortium. Eur Urol. 2019 ; 76 : 861-7.
PubMed
21) Ged Y, et al. Systemic therapy for advanced clear cell renal cell carcinoma after discontinuation of immune-oncology and VEGF targeted therapy combinations. BMC Urol. 2020 ; 20 : 84.
PubMed
22) Zhu J, et al. Biomarkers of immunotherapy in urothelial and renal cell carcinoma : PD-L1, tumor mutational burden, and beyond. J Immunother Cancer. 2018 ; 6 : 4.
PubMed
23) Rini BI, et al. The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC). J Immunother Cancer. 2019 ; 7 : 354.
 
24) Rini BI, et al. Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151) : a multicentre, open-label, phase 3, randomised controlled trial. Lancet. 2019 ; 393 : 2404-15.
PubMed
25) Powles T, et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211) : a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2018 ; 391 : 748-57.
 
26) Barlesi F, et al. Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200) : an open-label, randomised, phase 3 study. Lancet Oncol. 2018 ; 19 : 1468-79.
 
P.40 掲載の参考文献
1) Motzer RJ, et al. Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma : 42-month follow-up of a randomized phase 3 clinical trial. J Immunother Cancer. 2020 ; 8 : e000891.
PubMed
2) Motzer RJ, et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med. 2018 ; 378 : 1277-90.
PubMed
3) Rini BI, et al. Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med. 2019 ; 380 : 1116-27.
PubMed
4) Motzer RJ, et al. Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med. 2019 ; 380 : 1103-15.
PubMed
5) Motzer RJ, et al. CheckMate 214 investigators. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma : extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. Lancet Oncol. 2019 ; 20 : 1370-85.
PubMed
6) Choueiri TK, et al. Updated efficacy results from the JAVELIN Renal 101 trial : first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma. Ann Oncol. 2020 ; 31 : 1030-9.
PubMed
7) Powles T, et al. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426) : extended follow-up from a randomised, openlabel, Phase 3 trial. Lancet Oncol. 2020. Online ahead of print.
 
8) Motzer RJ, et al. Nivolumab versus everolimus in patients with advanced renal cell carcinoma : Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial. Cancer. 2020. Online ahead of print.
 
9) Escudier B, et al. Efficacy of Nivolumab plus Ipilimumab According to Number of IMDC Risk Factors in CheckMate 214. Eur Urol. 2020 ; 77 : 449-53.
PubMed
10) Tomita Y, et al. Treatment-free survival after discontinuation of immuno-checkpoint therapy, and outcome of subsequent molecular targeted therapy : Retrospective study of Japanese metastatic renal cell carcinoma patients (after I-O study). J Clin Oncol. 2020 ; 38 Suppl : 677.
 
11) Choueiri TK, et al. Nivolumab plus Cabozantinib Outperforms Sunitinib in Advanced Renal Cell Carcinoma. ESMO2020. (presentation ID : 6960)
 

III RCC Long - term prognosis RCC薬物療法のリスク分類別の長期成績改善の変遷

P.52 掲載の参考文献
1) Motzer RJ, et al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 2015 ; 373 : 1803-13.
PubMed
2) Motzer RJ, et al. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. N Engl J Med. 2018 ; 378 : 1277-90.
PubMed
3) Rini BI, et al. Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med. 2019 ; 380 : 1116-27.
PubMed
4) Motzer RJ, et al. Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med. 2019 ; 380 : 1103-15.
PubMed
5) Choueiri TK, et al. Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 2015 ; 373 : 1814-23.
PubMed
6) Motzer RJ, et al. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol. 2002 ; 20 : 289-96.
PubMed
7) Heng DYC, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents : results from a large, multicenter study. J Clin Oncol. 2009 ; 27 : 5794-9.
 
8) Naito S, et al. Prognosis of Japanese metastatic renal cell carcinoma patients in the cytokine era : a cooperative group report of 1463 patients. Eur Urol. 2010 ; 57 : 317-25.
 
9) Shinohara N, et al. Is Memorial Sloan-Kettering Cancer Center risk classification appropriate for Japanese patients with metastatic renal cell carcinoma in the cytokine era? Urol Oncol. 2013 ; 31 : 1276-82.
PubMed
10) Motzer RJ, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007 ; 356 : 115-24.
PubMed
11) Motzer RJ, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009 ; 27 : 3584-90.
PubMed
12) Rini BI, et al. Sunitinib in Patients With Metastatic Renal Cell Carcinoma : Clinical Outcome According to International Metastatic Renal Cell Carcinoma Database Consortium Risk Group. Clin Genitourin Cancer. 2018 ; 16 : 298-304.
PubMed
13) Schmidinger M, et al. Real-world Experience With Sunitinib Treatment in Patients With Metastatic Renal Cell Carcinoma : Clinical Outcome According to Risk Score. Clin Genitourin Cancer. 2020 ; 18 : e588-97.
PubMed
14) Savard MF, et al. Real-World Assessment of Clinical Outcomes Among First-Line Sunitinib Patients with Clear Cell Metastatic Renal Cell Carcinoma (mRCC) by the International mRCC Database Consortium Risk Group. Oncologist. 2020 ; 25 : 422-30.
PubMed
15) Lalani AA, et al. First-line sunitinib or pazopanib in metastatic renal cell carcinoma : The Canadian experience. Can Urol Assoc J. 2017 ; 11 : 112-7.
 
16) Perez-Valderrama B, et al. Validation of the International Metastatic Renal-Cell Carcinoma Database Consortium (IMDC) prognostic model for first-line pazopanib in metastatic renal carcinoma : the Spanish Oncologic Genitourinary Group (SOGUG) SPAZO study. Ann Oncol. 2016 ; 27 : 706-11.
PubMed
17) Tanaka N, et al. External Validation of the MSKCC and IMDC Risk Models in Patients Treated with Targeted Therapy as a First-line and Subsequent Second-line Treatment : A Japanese Multi-institutional Study. Eur Urol Focus. 2016 ; 2 : 303-9.
PubMed
18) Motzer RJ, et al. Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma : 42-month follow-up of a randomized phase 3 clinical trial. J Immunother Cancer. 2020 ; 8 : e000891.
PubMed
19) European Association of Urology. EAU Guidelines : Renal Cell Carcinoma. 2020. https://uroweb.org/guideline/renal-cell-carcinoma/, (accessed : 2020-10-15)
 
20) National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN GuidelinesR) : Kidney Cancer NCCN Evidence BlocksTM Version 1. 2021. 2020. https://www.nccn.org/professionals/physician_gls/pdf/kidney_blocks.pdf, (accessed : 2020-10-15)
 
21) Choueiri TK, et al. Updated efficacy results from the JAVELIN Renal 101 trial : first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma. Ann Oncol. 2020 ; 31 : 1030-9.
PubMed
22) 日本泌尿器科学会. 腎癌診療ガイドライン 2017年版 2020年アップデート内容. 2020. https://www.urol.or.jp/lib/files/other/guideline/33_renal_cancer_2017_rev2020_info.pdf, (閲覧 : 2020-10-12)
 
23) Rini BI, et al. Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for metastatic renal cell carcinoma (mRCC) : Outcomes in the combined IMDC intermediate/poor risk and sarcomatoid subgroups of the phase 3 KEYNOTE-426 study. J Clin Oncol. 2019 ; 37 Suppl : 4500.
 
24) Plimack ER, et al. Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced renal cell carcinoma (RCC) : Updated analysis of KEYNOTE-426. J Clin Oncol. 2020 ; 38 Suppl : 5001.
 
25) Rini BI, et al. Patients with mRCC express differential gene-expression signatures that associate with improved PFS following atezolizumab plus bevacizumab versus sunitinib. ESMO 2018. Munich. 2018.
 
P.60 掲載の参考文献
1) 日本泌尿器科学会 (編).腎癌診療ガイドライン 2017年版 補足. 2020. https://www.urol.or.jp/lib/files/other/guideline/33_renal_cancer_2017_rev2020_info.pdf, (閲覧 : 2020-09-25)
 
2) Motzer RJ, et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol. 2004 ; 22 : 454-63.
PubMed
3) Heng DY, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents : results from a large, multicenter study. J Clin Oncol. 2009 ; 27 : 5794-9.
PubMed
4) Motzer RJ, et al. Effect of cytokine therapy on survival for patients with advanced renal cell carcinoma. J Clin Oncol. 2000 ; 18 : 1928-35.
PubMed
5) Interferon-alpha and survival in metastatic renal carcinoma : early results of a randomised controlled trial. Medical Research Council Renal Cancer Collaborators. Lancet. 1999 ; 353 : 14-7.
PubMed
6) Motzer RJ, et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol. 1999 ; 17 : 2530-40.
PubMed
7) Pal SK, et al. Disease-specific survival in de novo metastatic renal cell carcinoma in the cytokine and targeted therapy era. PLoS One. 2013 ; 8 : e63341.
PubMed
8) Pal SK, et al. Real-world survival outcomes and prognostic factors among patients receiving first targeted therapy for advanced renal cell carcinoma : a SEER-medicare database analysis. Clin Genitourin Cancer. 2017 ; 15 : e573-82.
PubMed
9) Atkinson BJ, et al. Clinical outcomes for patients with metastatic renal cell carcinoma treated with alternative sunitinib schedules. J Urol. 2014 ; 191 : 611-8.
PubMed
10) Motzer RJ, et al. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. N Engl J Med. 2018 ; 378 : 1277-90.
PubMed
11) Motzer RJ, et al. Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma : 42-month follow-up of a randomized phase 3 clinical trial. J Immunother Cancer. 2020 ; 8 : e000891.
PubMed
12) Escudier B, et al. Efficacy of nivolumab plus ipilimumab according to number of IMDC risk factors in CheckMate 214. Eur Urol. 2020 ; 77 : 449-53.
PubMed
13) Rini BI, et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019 ; 380 : 1116-27.
PubMed
14) Powles T, et al. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426) : extended follow-up from a randomised, open label, Phase 3 trial. Lancet Oncol. 2020. Online ahead of print.
 
15) Motzer, RJ, et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019 ; 380 : 1103-15.
PubMed
16) Sella A, et al. Heterogeneity of patients with intermediate-prognosis metastatic renal cell carcinoma treated with sunitinib. Clin Genitourin Cancer. 2017 ; 15 : 291-9.e1.
 
17) Teishima J, et al. Prognostic significance of C-reactive protein in patients with intermediate-risk metastatic renal cell carcinoma treated with molecular targeted therapy. Oncol Lett. 2014 ; 8 : 881-5.
PubMed
18) Takamatsu K, et al. Prognostic value of baseline serum C-reactive protein level in intermediate-risk group patients with metastatic renal-cell carcinoma treated by first-line vascular endothelial growth factor-targeted therapy. Clin Genitourin Cancer. 2018 ; 16 : e927-33.
 
19) Tanaka N, et al. Prognostic value of neutrophil-to-lymphocyte ratio in patients with metastatic renal cell carcinoma treated with first-line and subsequent second-line targeted therapy : A proposal of the modified-IMDC risk model. Urol Oncol. 2017 ; 35 : 39. e19-28.
PubMed
20) Teishima J, et al. Impact of the systemic immune-inflammation index for the prediction of prognosis and modification of the risk model in patients with metastatic renal cell carcinoma treated with first-line tyrosine kinase inhibitors. Can Urol Assoc J. 2020. Online ahead of print.
 
21) Teishima J, et al. The effect of kinetics of C-reactive protein in the prediction of overall survival in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitor. Urol Oncol. 2017 ; 35 : 662. e1-7.
PubMed
22) Teishima J, et al. C-reactive protein can be used to predict the therapeutic effects of nivolumab in patients with metastatic renal cell carcinoma. Int J Urol. 2019 ; 26 : 1076-7.
PubMed
23) Teishima J, et al. Normalization of C-reactive protein levels following cytoreductive nephrectomy in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors is associated with improved overall survival. Urol Oncol. 2018 ; 36 : 339. e9-15.
PubMed
24) Naito S, et al. Prognosis of Japanese metastatic renal cell carcinoma patients in the cytokine era : a cooperative group report of 1463 patients. Eur Urol. 2010 ; 57 : 317-25.
 
P.71 掲載の参考文献
1) Motzer RJ, et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol. 1999 ; 17 : 2530-40.
PubMed
2) Motzer RJ, et al. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol. 2002 ; 20 : 289-96.
PubMed
3) Naito S, et al. Prognosis of Japanese metastatic renal cell carcinoma patients in the cytokine era : a cooperative group report of 1463 patients. Eur Urol. 2010 ; 57 : 317-25.
 
4) Shinohara N, et al. Multicenter phase II trial of combination therapy with meloxicam, a cox-2 inhibitor, and natural interferon-alpha for metastatic renal cell carcinoma. Jpn J Clin Oncol. 2009 ; 39 : 720-6.
PubMed
5) Tatokoro M, et al. Phase-II trial of combination treatment of interferon-α, cimetidine, cyclooxygenase-2 inhibitor and renin-angiotensin-system inhibitor (I-CCA therapy) for advanced renal cell carcinoma. Cancer Sci. 2011 ; 102 : 137-43.
 
6) Wahlgren T, et al. Treatment and overall survival in renal cell carcinoma : a Swedish population-based study (2000-2008). Br J Cancer. 2013 ; 108 : 1541-9.
PubMed
7) Heng DY, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents : results from a large, multicenter study. J Clin Oncol. 2009 ; 27 : 5794-9.
PubMed
8) Shinohara N, et al. Prognosis of Japanese patients with previously untreated metastatic renal cell carcinoma in the era of molecular-targeted therapy. Cancer Sci. 2015 ; 106 : 618-26.
PubMed
9) Ito K, et al. Impact of inflammatory marker levels one month after the first-line targeted therapy initiation on progression-free survival prediction in patients with metastatic clear cell renal cell carcinoma. Jpn J Clin Oncol. 2019 ; 49 : 69-76.
PubMed
10) Tanaka N, et al. Effect of reclassification of the IMDC model in patients with metastatic renal cell carcinoma treated with targeted therapy in the first-line and second-line settings. Urol Oncol. 2016 ; 34 : 293. e17-25.
PubMed
11) 日本泌尿器科学会 (編). 腎癌診療ガイドライン 2017年版. CQ3 : 進行腎癌に対する一次分子標的治療は何が推奨されるか? 大阪 : メディカルビュー社 ; 2017, p. 85-88.
 
12) Hudes G, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007 ; 356 : 2271-81.
 
13) Motzer RJ, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007 ; 356 : 115-24.
PubMed
14) Tannir NM, et al. Temsirolimus versus Pazopanib (TemPa) in Patients with Advanced Clear-cell Renal Cell Carcinoma and Poor-risk Features : A Randomized Phase II Trial. Eur Urol Oncol. 2019 : S2588-9311 (19) 30079-3.
 
15) Motzer RJ, et al. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. N Engl J Med. 2018 ; 378 : 1277-90.
PubMed
16) Cella D, et al. Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214) : a randomised, phase 3 trial. Lancet Oncol. 2019 ; 20 : 297-310.
PubMed
17) Motzer RJ, et al. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma : extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. Lancet Oncol. 2019 ; 20 : 1370-85.
PubMed
18) Escudier B, et al. Efficacy of Nivolumab plus Ipilimumab According to Number of IMDC Risk Factors in CheckMate 214. Eur Urol. 2020 ; 77 : 449-53.
PubMed
19) Tannir NM, et al. Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-Line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma. Clin Cancer Res. 2020. Online ahead of print.
 
20) Rassy E, et al. Tyrosine kinase inhibitors and immunotherapy combinations in renal cell carcinoma. Ther Adv Med Oncol. 2020 ; 12 : 1758835920907504.
PubMed
21) Rini BI, et al. Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med. 2019 ; 380 : 1116-27.
PubMed
22) Powles T, et al. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426) : extended follow-up from a randomised, open-label, Phase 3 trial. Lancet Oncol. 2020. Online ahead of print.
 
23) Motzer RJ, et al. Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med. 2019 ; 380 : 1103-15.
PubMed
24) Choueiri TK, et al. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR) : final results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2016 ; 17 : 917-27.
PubMed
25) Choueiri TK, et al. Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial) : Progression-free survival by independent review and overall survival update. Eur J Cancer. 2018 ; 94 : 115-25.
 

IV 特別寄稿

P.76 掲載の参考文献
1) 日本泌尿器科学会, 日本病理学会, 日本医学放射線学会 (編). 泌尿器科・病理・放射線科 腎癌取扱い規約 第5版. 大阪 : メディカルレビュー社 ; 2020.
 
2) Silverman SG, et al. Bosniak Classification of Cystic Renal Masses, Version 2019 : An Update Proposal and Needs Assessment. Radiology. 2019 ; 292 : 475-88.
PubMed
3) UICC日本委員会TNM委員会 (訳). TNM悪性腫瘍の分類 第8版 日本語版. 東京 : 金原出版 ; 2017.
 
4) 日本癌治療学会 (編). 日本癌治療学会リンパ節規約. 東京 : 金原出版 ; 2002.
 
5) 有害事象共通用語規準 v5.0 日本語訳JCOG版 (略称 : CTCAE v5.0-JCOG) [CTCAE v 5.0/MedDRAv20.1/MedDRA/J v21.1対応 2019年9月5日]. 2019. http://www.jcog.jp/doctor/tool/CTCAEv5J_20190905_v22_1.pdf (閲覧 : 2020-09-04)
 
6) JCOG術後合併症規準 (Clavien-Dindo分類) v2.0 (2013年4月11日承認). 2013. http://www.jcog.jp/doctor/tool/JCOG_Clavien-Dindo_ver2.0.pdf, (閲覧 : 2020-09-04)
 

書評

最近チェックした商品履歴

Loading...